Several reports have found that serum levels of FGF21 were increased in subjects with non-alcoholic fatty liver disease, hyperlipidemia, hypertension, and atherosclerosis [36–39]. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.